Aim 1 is to generate and characterize 10 IgG monoclonal aCLs.
Aim 2 is to analyze monoclonal aCLs in the in vivo fetal loss model.
Aim 3 is to identify and characterize the mimetics for pathogenic aCL.
Aim 4 is to do immunological and functional studies of antibodies against mimetics in APS patients.
Aim 5 is to apply mimetics to study pathogenic aCL in APS patients and controls.
Showing the most recent 10 out of 21 publications